FIBROGEN INC
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit · Incorporation By Reference | |||||
|---|---|---|---|---|---|
| Number | Exhibit Description | Form | SEC File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of FibroGen, Inc. | 8-K | 001-36740 | 3.1 | 11/21/2014 |
| 3.2 | Amended and Restated Bylaws of FibroGen, Inc. | 8-K | 001-36740 | 3.1 | 04/04/2025 |
| 3.3 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation of FibroGen, Inc. | 8-K | 001-36740 | 3.1 | 06/12/2025 |
| 4.1 | Form of Common Stock Certificate. | 8-K | 001-36740 | 4.1 | 11/21/2014 |
| 4.2 | Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014. | S-1/A | 333-199069 | 4.17 | 10/24/2014 |
| 10.1*† | Amendment No.2 to Second Amended and Restated Exclusive License Agreement, by and among Eluminex Biosciences (Suzhou) Limited, FibroGen, Inc., FibroGen International (Hong Kong) Limited, FibroGen (China) Medical Technology Development Co., Ltd., and Beijing Falikang Pharmaceutical Co., Ltd., dated as of August 5, 2025. | — | — | — | — |
| 10.2*† | Termination Agreement, by and between, FibroGen, Inc. and AstraZeneca AB, effective as of February 25, 2024, as amended and restated on August 29, 2025. | — | — | — | — |
| 10.3*† | Amendment to Share Purchase Agreement, by and among AstraZeneca Treasury Limited, FibroGen China Anemia Holdings, Ltd., and FibroGen, Inc., dated as of August 29, 2025. | — | — | — | — |
| 31.1* | Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | — | — | — | — |
| 31.2* | Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | — | — | — | — |
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)). | — | — | — | — |
| 101.INS | Inline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | — | — | — | — |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | — | — | — | — |
| 104 | Cover Page formatted as inline XBRL and contained in Exhibits 101. | — | — | — | — |
- Filed herewith.
† Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.
- Indicates a management contract or compensatory plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.